NASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis $2.46 +0.02 (+0.82%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.40▼$2.5750-Day Range$2.04▼$2.8652-Week Range$1.55▼$4.27Volume107,533 shsAverage Volume148,108 shsMarket Capitalization$152.88 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Galectin Therapeutics alerts: Email Address Galectin Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside347.2% Upside$11.00 Price TargetShort InterestBearish11.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 3 Articles This WeekInsider TradingAcquiring Shares$4,046 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.79) to ($1.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.22 out of 5 starsMedical Sector719th out of 910 stocksPharmaceutical Preparations Industry338th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingGalectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGalectin Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Galectin Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.59% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 30.3, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently increased by 6.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GALT. Previous Next 1.8 News and Social Media Coverage News SentimentGalectin Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,046.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.68% of the stock of Galectin Therapeutics is held by institutions.Read more about Galectin Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.79) to ($1.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Galectin Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Galectin Therapeutics Stock (NASDAQ:GALT)Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Read More GALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GALT Stock News HeadlinesSeptember 3, 2024 | globenewswire.comGalectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 30, 2024 | americanbankingnews.comTraders Buy Large Volume of Galectin Therapeutics Put Options (NASDAQ:GALT)September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and with Strong Cash PositionAugust 13, 2024 | globenewswire.comGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business UpdateAugust 1, 2024 | globenewswire.comGalectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical OfficerJuly 30, 2024 | finance.yahoo.comGalectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%June 4, 2024 | globenewswire.comGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 CongressSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.May 18, 2024 | seekingalpha.comGalectin Therapeutics GAAP EPS of -$0.19May 15, 2024 | investorplace.comGALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business UpdateMay 13, 2024 | finance.yahoo.comGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect ConferenceApril 30, 2024 | money.usnews.comGalectin Therapeutics IncApril 20, 2024 | morningstar.comGalectin Therapeutics Inc GALTApril 9, 2024 | markets.businessinsider.comGalectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of BelapectinApril 9, 2024 | finance.yahoo.comGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisApril 5, 2024 | investorplace.comGALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023See More Headlines Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GALT CUSIPN/A CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+347.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,070,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-184.63% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.01) per share Price / Book-2.44Miscellaneous Outstanding Shares62,148,000Free Float29,396,000Market Cap$152.88 million OptionableOptionable Beta0.62 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Joel Lewis (Age 54)President, CEO & Director Comp: $907.72kMr. Jack W. Callicutt CPA (Age 57)CFO, Treasurer & Corporate Secretary Comp: $521.47kDr. Pol F. Boudes M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $730.33kRobert TrittGeneral CounselMr. Jeff KatstraHead of CMC & Pharmaceutical DevelopmentMs. Beth KnowlesExecutive Assistant & Officer ManagerMore ExecutivesKey CompetitorsEnochian BiosciencesNASDAQ:ENOBLumos PharmaNASDAQ:LUMOKindred BiosciencesNASDAQ:KINAstria TherapeuticsNASDAQ:ATXSPharvarisNASDAQ:PHVSView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 100,658 shares on 9/5/2024Ownership: 0.162%Richard A Jr. ZordaniBought 1,759 shares on 8/23/2024Total: $4,045.70 ($2.30/share)Squarepoint Ops LLCBought 36,139 shares on 8/14/2024Ownership: 0.135%Marshall Wace LLPBought 18,825 shares on 8/14/2024Ownership: 0.030%Rhumbline AdvisersBought 19,275 shares on 8/1/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions GALT Stock Analysis - Frequently Asked Questions How have GALT shares performed this year? Galectin Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, GALT stock has increased by 48.2% and is now trading at $2.46. View the best growth stocks for 2024 here. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. Who are Galectin Therapeutics' major shareholders? Top institutional investors of Galectin Therapeutics include Commonwealth Equity Services LLC (0.78%), Sanctuary Advisors LLC (0.16%), Squarepoint Ops LLC (0.14%) and Bank of New York Mellon Corp (0.10%). Insiders that own company stock include James C Czirr, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Jack W Callicutt, Joel Lewis, Fund LP 10X and Elissa J Schwartz. View institutional ownership trends. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). This page (NASDAQ:GALT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
